Kraig Biocraft Laboratories' CEO Issues Corporate State of Affairs Letter
December 07 2010 - 6:05AM
Marketwired
From Kim Thompson, CEO Kraig Biocraft Laboratories, Inc.
(PINKSHEETS: KBLB);
Dear Kraig Biocraft Laboratories Community,
For the past five years, I have been privileged to be a part of
the legacy and vision of a truly revolutionary biotechnology
company, Kraig Biocraft Laboratories, but this is, by far, the most
exciting holiday season for members of the Kraig team and Kraig
shareholders.
2010 has already been a tremendous year, as we have made
scientific history with our development of twenty separate lines of
transgenic silkworm. Among the products which we have invented and
are producing in the laboratory is "Monster Silk™", a genetically
engineered composite of spider silk and silkworm silk which is
significantly stronger and more flexible than commercial silk.
While we still have a few weeks to go in 2010, I wanted to share
with you some thoughts about our corporate state of affairs,
because I firmly believe that we are destined for even greater
achievements in 2011.
We are rapidly moving towards commercialization and are solidly
committed to executing a focused plan of developing strategic
partnerships, as well as merger and acquisition opportunities,
synced to our current technologies and the anticipated future
generations of spider silk technologies. We have always believed
that the shortest and surest path to commercialize the products we
develop in the laboratory is through partnership with companies
which already possess significant market share in our target
markets.
Our aggressive commercialization plan benefits from the addition
of two world class experts in corporate growth, Henry Wendt and
Raymond Kutsunai, to the Business Advisory Board. I believe that
their leadership and experience, especially in the area of mergers
and acquisitions, will make a significant contribution to the
commercialization of our breakthroughs in biotechnology and polymer
science. I also believe that the addition of these outstanding team
members confirms that we are headed in the right direction. We have
also identified a potential Business Advisory Board member who has
impeccable technical textile market expertise, and we anticipate
making an announcement in the near future.
Kraig remains on track for product optimization and
commercialization. I believe that our partnership, merger and/or
acquisition prospects are very strong. I also believe our
aggressive business model strongly leverages the Company's
position, and will reap exciting results in 2011.
At the same time I have taken steps to accelerate our research
and development work in the laboratory to leverage what we have
already invented and discovered into a second generation of new
technologies. We anticipate that this second generation technology
will be unveiled in 2011.
We remain committed to working towards the rapid
commercialization of the most revolutionary products imaginable.
2011 will be an exciting time for Kraig Biocraft Laboratories, and
I personally am anticipating the growth of our company in the New
Year. Our shareholders have come to appreciate the patience and
commitment required to make Kraig a world class technical textiles
leader. I would like to take this opportunity to thank them, as
well as our dedicated Scientific Advisory Board and Business
Advisory Board, for their ongoing support.
Lastly, I extend my sincere best wishes to you and your families
for the holidays. So, on behalf of Kraig Biocraft Laboratories, I
would like to wish you a Happy Hanukah and a Merry Christmas, and a
healthy and prosperous New Year!
Kim Thompson, CEO Kraig Biocraft Laboratories, Inc.
To learn more about Kraig Biocraft Laboratories please visit
www.KraigLabs.com and go to the video page to see the extraordinary
accomplishments of this small biotechnology company.
Statements in this press release about the company's future and
expectations other than historical facts are "forward-looking
statements." These statements are made on the basis of management's
current views and assumptions. As a result, there can be no
assurance that management's expectations will necessarily come to
pass. These forward-looking statements generally can be identified
by phrases such as "believes," "plans," "expects," "anticipates,"
"foresees," "hopes," "develops," "researching," "research,"
"potential," "implications," "could" or other words or phrases of
similar import. Similarly, statements in this release that describe
the Company's business strategy, outlook, objectives, plans,
intentions or goals should all be considered forward-looking
statements. All such forward-looking statements are subject to
certain risks and uncertainties that could cause actual results to
differ materially from those in forward-looking statements.
Management cautions that its ability to further its research, and
create commercially-viable products may be affected by the
competitive environment, the Company's financial condition and its
ability to raise sufficient capital to meet the financial
obligations of its business plan and to fund its continuing
operations.
Contact: Ben Hansel (720) 288-8495 Email Contact
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From May 2024 to Jun 2024
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From Jun 2023 to Jun 2024